US FDA approves use of Emergent’s smallpox vaccine for people at high risk of mpox

(Reuters) – Emergent BioSolutions on Thursday said the U.S. Food and Drug Administration (FDA) had approved expanded use of its ACAM2000 smallpox vaccine to include people at high risk for mpox infection.

(Reporting by Shivani Tanna in Bengaluru; Editing by Maju Samuel)